Related references
Note: Only part of the references are listed.Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer
Huajia Zhang et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Progress and challenges of immunotherapy in triple-negative breast cancer
Yinxing Zhu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer
Han Zhang et al.
CANCER SCIENCE (2021)
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy
Sundee Dees et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
HN1L promotes migration and invasion of breast cancer by up-regulating the expression of HMGB1
Dechuang Jiao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
The immunomodulatory effects of endocrine therapy in breast cancer
Huanhuan Huang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress
Zhusheng Huang et al.
NATURE COMMUNICATIONS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients
Elham Safarzadeh et al.
FRONTIERS IN IMMUNOLOGY (2021)
Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments
Adrien Procureur et al.
CANCERS (2021)
Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens
Junxia Gao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2021)
A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
Diwakar Bastihalli Tukaramrao et al.
CANCERS (2021)
A Comprehensive Investigation to Reveal the Relationship Between Plasmacytoid Dendritic Cells and Breast Cancer by Multiomics Data Analysis
Saisai Tian et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
Foluso O. Ademuyiwa et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Breast cancer immunotherapy: Current and novel approaches
Khadijeh Barzaman et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
David A. Bernal-Estevez et al.
FRONTIERS IN IMMUNOLOGY (2021)
Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies
Angela-Patricia Hernandez et al.
CANCERS (2021)
Advancing to the era of cancer immunotherapy
Yun Wang et al.
CANCER COMMUNICATIONS (2021)
Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy
Asumi Sakaguchi et al.
BREAST CANCER RESEARCH (2021)
Calreticulin and cancer
Jitka Fucikova et al.
CELL RESEARCH (2021)
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Filippo Veglia et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer
Ryungsa Kim et al.
EJSO (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+MDSCs and Promotion of Circulating IFN-γ plus Myeloid Cells in the 4T1 Metastatic Breast Cancer Model
Jozsef A. Balog et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Neoadjuvant or adjuvant chemotherapy in early breast cancer?
Filippo Montemurro et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Lifting the innate immune barriers to antitumor immunity
Carla Rothlin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model
Silvia Elena Santana-Krimskaya et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers
Konstantinos Venetis et al.
CANCER TREATMENT REVIEWS (2020)
Immunological Significance of HMGB1 Post-Translational Modification and Redox Biology
Man Sup Kwak et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
Kabir A. Khan et al.
NPJ BREAST CANCER (2020)
Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer
Yue Sun et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J. A. Kyte et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J. A. Kyte et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics
Johny E. Fares et al.
CANCER TREATMENT REVIEWS (2020)
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Quantitative multiplex immunofluorescence analysis identifies infiltratingPD1+CD8+and CD8+T cells as predictive of response to neoadjuvant chemotherapy in breast cancer
Hongling Liang et al.
THORACIC CANCER (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Masanori Oshi et al.
CANCERS (2020)
Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy
Miguel Angel Galvan Morales et al.
MOLECULES (2020)
Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
Claudia Ceci et al.
CANCERS (2020)
Induction of immunogenic cell death of cancer cells through nanoparticle-mediated dual chemotherapy and photothermal therapy
Niloofar Heshmati Aghda et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
Adjuvant and neoadjuvant therapy for breast cancer
Tadahiko Shien et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
A. F. de Groot et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients
Ryungsa Kim et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
James B. Wing et al.
IMMUNITY (2019)
Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study
Song Yao et al.
CLINICAL EPIGENETICS (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
Javier Cortes et al.
FUTURE ONCOLOGY (2019)
Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy - potential markers for predicting breast cancer recurrence?
Anna Rothammer et al.
RADIATION ONCOLOGY (2019)
The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases
Mao Wang et al.
ANTIOXIDANTS & REDOX SIGNALING (2019)
Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis
Hui Cai et al.
ADVANCED SCIENCE (2019)
DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation
Joel Zindel et al.
Annual Review of Pathology-Mechanisms of Disease (2019)
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
E. Krasniqi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
Yosi Gilad et al.
SCIENTIFIC REPORTS (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
Luciana Molinero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Tuberculosis following PD-1 blockade for cancer immunotherapy
Daniel L. Barber et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma
Keita Aoto et al.
ONCOLOGY REPORTS (2018)
Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy
David A. Bernal-Estevez et al.
BMC CANCER (2018)
Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
Stefania Orecchioni et al.
BRITISH JOURNAL OF CANCER (2018)
Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy
Nikolai Litviakov et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Checkpoint inhibitors in breast cancer - Current status
Anne Polk et al.
CANCER TREATMENT REVIEWS (2018)
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies
Jacob P. van Vloten et al.
JOURNAL OF IMMUNOLOGY (2018)
Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment
Garcia-Chagollan Mariel et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)
Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients
Kai-Rong Lin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Dynamic and significant changes of T-cell subgroups in breast cancer patients during surgery and chemotherapy
Wen-Hui Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment
Jing Zhang et al.
MOLECULES (2018)
Linking cellular stress responses to systemic homeostasis
Lorenzo Galluzzi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells
David H. Raulet et al.
IMMUNOLOGICAL REVIEWS (2017)
High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
Marco E. Bianchi et al.
IMMUNOLOGICAL REVIEWS (2017)
Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment
Sushil Kumar et al.
IMMUNOLOGICAL REVIEWS (2017)
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy
Hua Zheng et al.
IMMUNOTHERAPY (2017)
The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers
Viriya Kaewkangsadan et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Robert Wesolowski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Awareness and current knowledge of breast cancer
Muhammad Akram et al.
BIOLOGICAL RESEARCH (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways
Mohammadreza Zamanian et al.
CANCER CELL INTERNATIONAL (2016)
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy
Jae-Hyun Park et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
H. Raza Ali et al.
PLOS MEDICINE (2016)
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
Ruth Exner et al.
CANCER MEDICINE (2016)
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer
Viriya Kaewkangsadan et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
Rashmi Verma et al.
BREAST CANCER RESEARCH (2016)
Progress in adjuvant chemotherapy for breast cancer: an overview
Jesus Anampa et al.
BMC MEDICINE (2015)
Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
E. Muraro et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery
Chandan Verma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells
Kamolporn Amornsupak et al.
BMC CANCER (2014)
Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer
Xin Chen et al.
PLOS ONE (2014)
Tumor-infiltrating lymphocytes in breast cancer A new predictor for responses to therapy
Yasmin Issa-Nummer et al.
ONCOIMMUNOLOGY (2014)
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer
Tobias Arnold et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
James W. Hodge et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
A. J. Montero et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Regulatory T cells increase in breast cancer and in stage IV breast cancer
Zhi-kuan Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
Shan Wan et al.
PLOS ONE (2012)
CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4
Y. Zhu et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2011)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. M. Liu et al.
BRITISH JOURNAL OF CANCER (2010)
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
Fariba Mozaffari et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
Galina V. Shurin et al.
JOURNAL OF IMMUNOLOGY (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
Ping Zhang et al.
MOLECULAR IMMUNOLOGY (2008)
Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens
N. Wijayahadi et al.
JOURNAL OF CHEMOTHERAPY (2007)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
R Kass et al.
JOURNAL OF SURGICAL RESEARCH (2003)
Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro
P Correale et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Proteomics reveals protein profile changes in doxorubicin - treated MCF-7 human breast cancer cells
ST Chen et al.
CANCER LETTERS (2002)
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
N Tsavaris et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
